Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) EBT (2019 - 2025)

Historic EBT for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $359.6 million.

  • CureVac's EBT fell 1164.5% to $359.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.8 million, marking a year-over-year increase of 8903.19%. This contributed to the annual value of $204.0 million for FY2024, which is 17292.33% up from last year.
  • CureVac's EBT amounted to $359.6 million in Q3 2025, which was down 1164.5% from -$67.9 million recorded in Q2 2025.
  • CureVac's 5-year EBT high stood at $407.0 million for Q3 2024, and its period low was -$183.3 million during Q2 2021.
  • In the last 5 years, CureVac's EBT had a median value of -$61.6 million in 2023 and averaged -$24.9 million.
  • Per our database at Business Quant, CureVac's EBT plummeted by 245068.27% in 2022 and then surged by 86805.32% in 2024.
  • Over the past 5 years, CureVac's EBT (Quarter) stood at -$5.1 million in 2021, then tumbled by 2450.68% to -$131.3 million in 2022, then grew by 29.12% to -$93.1 million in 2023, then surged by 55.73% to -$41.2 million in 2024, then surged by 972.63% to $359.6 million in 2025.
  • Its last three reported values are $359.6 million in Q3 2025, -$67.9 million for Q2 2025, and $54.3 million during Q1 2025.